Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Test Protocol for Testing Anti-Viral Efficacy

26 Feb 2021 07:00

RNS Number : 4122Q
Byotrol PLC
26 February 2021
 

 

 

Byotrol Plc

("Byotrol" or the "Company")

 

Landmark test protocol for testing long-lasting anti-viral efficacy

 

 

Byotrol plc (AIM:BYOT), the specialist infection prevention and control company, is pleased to announce that it has developed and externally validated a new test for determining whether cleaning and sanitising products have long-lasting efficacy against viruses in real-life use.

· This new test determines whether sanitising and cleaning products offer any long-lasting protection against COVID-19

· Byotrol is now standing behind product efficacy claims supporting infection control products that offer 24-hour protection against viruses and bacteria in real-life conditions, where surfaces are frequently touched

· The Company believes that this new test could help minimise the spread of the virus when used in conjunction with the cleaning and sanitising of shops, schools and offices when they reopen

Byotrol has developed the new test in response to an increasing number of products claiming long-lasting efficacy against coronavirus, based on laboratory conditions which ignore the constant abrasion of surfaces in real-life environments (and which would then make many products ineffective).

 

Byotrol developed the industry standard test for long-lasting efficacy in real-life against bacteria and yeast in 2014 with the help of independent industry experts. The test, named PAS 2424:2014, was approved by the British Standards Institute (BSI) and is the only British standard to prove the efficacy of a disinfectant product over 24 hours. The PAS 2424:2014 test is currently being reviewed by the CEN Committee for approval as a new European EN test standard.

 

This new test for viruses simulates 'real-life' conditions by creating frequent abrasions on surfaces after products have been applied, to replicate frequent touching of surfaces throughout the day. The surfaces are then tested to see whether the product is still present and killing viruses. The test is limited to 24 hours, to ensure that the result is attributed to the efficacy of the product, not the length of time the virus has been left to dry out on a surface, which could result in a false positive.

 

This new test was performed internally in Byotrol's virology lab with the results being reviewed and validated externally by Professor James Stewart, Chair of Molecular Virology at the University of Liverpool, who commented: "A validation of the effectiveness of surface disinfectants against viruses using this test is an important step forward for the industry and consumers alike."

 

Byotrol plans to gain approval from the BSI again, to make this new test the British standard for proving the long-lasting efficacy of disinfectants against viruses.

 

The application of this test could help businesses and consumers select products which are proven to be effective in a variety of public spaces where surfaces are frequently touched, genuinely promoting public health.

 

 

 

Trevor Francis, Chief Technology Officer of Byotrol plc commented:

 

"Long-term surface protection against viruses is the holy grail that businesses in the hygiene sector are chasing currently. We have responded to a clear market need for clarity on which surface disinfectants continue to deactivate viruses in real-life environments and which don't. It's a huge win for consumers and the government as we return to normality beyond the pandemic."

 

 

Enquiries:

 

Byotrol plc

Trevor Francis - Chief Technology Officer

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance   020 7220 0500

Richard Chambers - ECM

 

Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon +44 (0)207 129 1474

byotrol@flagstaffcomms.com

 

 

 

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLGDDIXDDGBU
Date   Source Headline
6th Apr 202010:56 amRNSHolding(s) in Company
2nd Apr 202011:05 amRNSSecond Price Monitoring Extn
2nd Apr 202011:00 amRNSPrice Monitoring Extension
24th Mar 20209:05 amRNSSecond Price Monitoring Extn
24th Mar 20209:00 amRNSPrice Monitoring Extension
23rd Mar 20207:01 amRNSTrading Update
23rd Mar 20207:00 amRNSLicence and Product Supply Agreement with Tristel
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
13th Mar 20202:05 pmRNSSecond Price Monitoring Extn
13th Mar 20202:00 pmRNSPrice Monitoring Extension
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
28th Feb 20204:15 pmRNSHolding(s) in Company
30th Jan 20205:00 pmRNSDirector/PDMR Shareholding
30th Jan 20208:00 amRNSAcceleration of earn-out relating to Medimark
19th Dec 20197:00 amRNSInterim Results
14th Nov 201912:30 pmRNSResult of AGM
13th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20192:54 pmRNSHolding(s) in Company
11th Oct 20193:00 pmRNSRestoration - Byotrol Plc
11th Oct 20193:00 pmRNSPosting of Accounts, Notice of AGM and Restoration
1st Oct 20193:50 pmRNSHolding(s) in Company
1st Oct 20197:30 amRNSSuspension - BYOTROL PLC
30th Sep 201912:01 pmRNSPublication of accounts and temporary suspension
30th Sep 201912:00 pmRNSUnaudited Preliminary Results to 31 March 2019
25th Sep 20197:00 amRNSNotice of Results
3rd Sep 20199:08 amRNSNotice of Results
28th May 20197:00 amRNSAppointment of CFO & Award of Options
9th May 20197:00 amRNSTrading Update
15th Apr 201911:58 amRNSHolding(s) in Company
28th Feb 20197:00 amRNSEPA Approval and Target Roll-Out
31st Jan 20199:14 amRNSHolding(s) in Company
29th Jan 20197:00 amRNSAppointment of New Director & Award of Options
31st Dec 20187:00 amRNSGrant of Options
21st Dec 20181:41 pmRNSHolding(s) in Company
21st Dec 20181:41 pmRNSHolding(s) in Company
20th Dec 201812:07 pmRNSDirector Dealings
18th Dec 20187:00 amRNSInterim Results
14th Nov 201810:35 amRNSHolding(s) in Company
13th Nov 20184:00 pmRNSHolding(s) in Company
13th Nov 201811:20 amRNSDirector/PDMR Shareholding
12th Nov 20185:05 pmRNSHolding(s) in Company
21st Sep 20184:00 pmRNSResult of AGM
4th Sep 201811:15 amRNSPosting of Annual Report and Notice of AGM
3rd Sep 20184:48 pmRNSHolding(s) in Company
3rd Sep 20184:12 pmRNSHolding(s) in Company
24th Aug 201812:01 pmRNSDirector Dealing
24th Aug 20187:00 amRNSDirector Dealing
23rd Aug 201811:31 amRNSAcquisition of Medimark Scientific Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.